IL13RA2 targeted alpha particle therapy against glioblastomas

• Published in: Oncotarget Vol. 8; no. 26; pp. 42997 - 43007
• Main Authors: Sattiraju, Anirudh, Solingapuram Sai, Kiran Kumar, Xuan, Ang, Pandya, Darpan N, Almaguel, Frankis G, Wadas, Thaddeus J, Herpai, Denise M, Debinski, Waldemar, Mintz, Akiva
• Format: Journal Article
• Language: English
• Published: United States Impact Journals LLC 27.06.2017
• Subjects: Actinium - chemistry; Alpha Particles - therapeutic use; Animals; Brain Neoplasms - diagnosis; Brain Neoplasms - metabolism; Brain Neoplasms - pathology; Brain Neoplasms - radiotherapy; Cell Line, Tumor; Cell Proliferation - radiation effects; Copper Radioisotopes - chemistry; Cysteamine - administration & dosage; Cysteamine - analogs & derivatives; Cysteamine - chemistry; Disease Models, Animal; DNA Breaks, Double-Stranded - radiation effects; Gene Expression; Glioblastoma - diagnosis; Glioblastoma - metabolism; Glioblastoma - pathology; Glioblastoma - radiotherapy; Humans; Interleukin-13 Receptor alpha2 Subunit - antagonists & inhibitors; Interleukin-13 Receptor alpha2 Subunit - genetics; Interleukin-13 Receptor alpha2 Subunit - metabolism; Isotope Labeling; Male; Mice; Peptides - administration & dosage; Peptides - chemistry; Research Paper; X-Ray Microtomography; Xenograft Model Antitumor Assays; alpha particle therapy; Actinium-225; glioblastoma; IL13RA2; Copper-64
• ISSN: 1949-2553; 1949-2553
• DOI: 10.18632/oncotarget.17792

Glioblastoma (GBM) is the most aggressive primary malignant brain cancer that invariably results in a dismal prognosis. Chemotherapy and radiotherapy have not been completely effective as standard treatment options for patients due to recurrent disease. We and others have therefore developed molecular strategies to specifically target interleukin 13 receptor alpha 2 (IL13RA2), a GBM restricted receptor expressed abundantly on over 75% of GBM patients. In this work, we evaluated the potential of Pep-1L, a novel IL13RA2 targeted peptide, as a platform to deliver targeted lethal therapies to GBM. To demonstrate GBM-specificity, we radiolabeled Pep-1L with Copper-64 and performed in vitro cell binding studies, which demonstrated specific binding that was blocked by unlabeled Pep-1L. Furthermore, we demonstrated real-time GBM localization of [64Cu]Pep-1L to orthotopic GBMs using small animal PET imaging. Based on these targeting data, we performed an initial in vivo safety and therapeutic study using Pep-1L conjugated to Actinium-225, an alpha particle emitter that has been shown to potently and irreversibly kill targeted cells. We infused [225Ac]Pep-1L into orthotopic GBMs using convection-enhanced delivery and found no significant adverse events at injected doses. Furthermore, our initial data also demonstrated significantly greater overall, median and mean survival in treated mice when compared to those in control groups (p < 0.05). GBM tissue extracted from mice treated with [225Ac]Pep-1L showed double stranded DNA breaks, lower Ki67 expression and greater propidium iodide internalization, indicating anti-GBM therapeutic effects of [225Ac]Pep-1L. Based on our results, Pep-1L warrants further investigation as a potential targeted platform to deliver anti-cancer agents.